What one share of PDS Biotechnology holds
In addition, we are developing the Infectimune® T cell-activator in infectious diseases.
PDS Biotechnology’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.64 |
|---|---|
| Cash and investments | $0.10 |
| Book value | −$0.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$1.44 | — | — | — | $2.21 |
| 2020 | — | −$0.89 | — | — | — | $1.22 |
| 2021 | — | −$0.66 | — | — | — | $2.22 |
| 2022 | — | −$1.43 | — | — | — | $1.46 |
| 2023 | — | −$1.39 | $0.00 | −$1.09 | — | $0.79 |
| 2024 | — | −$1.03 | $0.00 | −$0.96 | — | $0.50 |
| 2025 | — | −$0.74 | $0.00 | −$0.60 | — | $0.17 |
Common questions about PDS Biotechnology
How much does one share of PDS Biotechnology earn?
Over the last 12 months, PDS Biotechnology lost $0.64 for each share.
Does PDS Biotechnology pay a dividend?
PDS Biotechnology didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is PDS Biotechnology’s book value per share?
PDS Biotechnology’s book value is negative (−$0.06 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of PDS Biotechnology have?
Each share of PDS Biotechnology has $0.10 of cash and investments, as of June 30, 2026.
Has PDS Biotechnology bought back shares?
PDS Biotechnology’s share count rose about 853% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.